Financing (Tables)

6 Months Ended

Jul. 03, 2020

Debt Disclosure [Abstract]

Components Of Debt

The following summarizes the key terms of the offerings in aggregate (€ in millions):

	Issue Date	Aggregate Principal Amount		Stated Annual Interest Rate		Issue Price (as % of Principal Amount)		Maturity Date	Interest Payment Dates (in arrears)
2024 Euronotes	March 30, 2020	€	750.0	1.700	%	99.931	%	March 30, 2024	March 30
2024 Euronotes	April 8, 2020	€	150.0	1.700	%	100.298	%	March 30, 2024	March 30
2026 Euronotes	March 30, 2020	€	500.0	2.100	%	99.717	%	September 30, 2026	September 30
2026 Euronotes	April 8, 2020	€	300.0	2.100	%	100.842	%	September 30, 2026	September 30
2030 Euronotes	March 30, 2020	€	500.0	2.500	%	99.642	%	March 30, 2030	March 30
2030 Euronotes	April 8, 2020	€	300.0	2.500	%	102.166	%	March 30, 2030	March 30

The components of the Company’s debt were as follows ($ in millions):

	July 3, 2020		December 31, 2019
Euro-denominated commercial paper (€1.5 billion and €4.6 billion, respectively)	$	1,680.4	$	5,146.2
U.S. dollar-denominated commercial paper	67.1		—
Zero-coupon LYONs due 2021	26.2		33.6
0.352% senior unsecured notes due 2021 (¥30.0 billion aggregate principal amount) (the “2021 Yen Notes”)	278.9		275.8
1.7% senior unsecured notes due 2022 (€800.0 million aggregate principal amount) (the “2022 Euronotes”)	897.7		894.8
Floating rate senior unsecured notes due 2022 (€250.0 million aggregate principal amount) (the “Floating Rate 2022 Euronotes”)	280.7		279.8
2.05% senior notes due 2022 (the “2022 Biopharma Notes”)	697.5		696.9
0.5% senior unsecured bonds due 2023 (CHF 540.0 million aggregate principal amount) (the “2023 CHF Bonds”)	572.2		558.9
1.7% senior notes due 2024 (€900.0 million aggregate principal amount) (the “2024 Euronotes”)	1,006.6		—
5-year revolving credit facility	1,247.8		—
2.2% senior unsecured notes due 2024 (the “2024 Biopharma Notes”)	696.4		696.2
2.5% senior unsecured notes due 2025 (€800.0 million aggregate principal amount) (the “2025 Euronotes”)	896.3		893.7
3.35% senior unsecured notes due 2025 (the “2025 U.S. Notes”)	497.5		497.3
0.2% senior unsecured notes due 2026 (€1.3 billion aggregate principal amount) (the “2026 Biopharma Euronotes”)	1,396.5		1,392.3
2.1% senior notes due 2026 (€800.0 million aggregate principal amount) (the “2026 Euronotes”)	895.1		—
0.3% senior unsecured notes due 2027 (¥30.8 billion aggregate principal amount) (the “2027 Yen Notes”)	285.6		282.5
1.2% senior unsecured notes due 2027 (€600.0 million aggregate principal amount) (the “2027 Euronotes”)	670.1		668.0
0.45% senior unsecured notes due 2028 (€1.3 billion aggregate principal amount) (the “2028 Biopharma Euronotes”)	1,394.6		1,390.1
1.125% senior unsecured bonds due 2028 (CHF 210.0 million aggregate principal amount) (the “2028 CHF Bonds”)	226.1		221.0
2.6% senior unsecured notes due 2029 (the “2029 Biopharma Notes”)	794.5		794.8
2.5% senior notes due 2030 (€800.0 million aggregate principal amount) (the “2030 Euronotes”)	898.7		—
0.75% senior unsecured notes due 2031 (€1.8 billion aggregate principal amount) (the “2031 Biopharma Euronotes”)	1,954.6		1,948.7
0.65% senior unsecured notes due 2032 (¥53.2 billion aggregate principal amount) (the “2032 Yen Notes”)	493.2		487.8
1.35% senior unsecured notes due 2039 (€1.3 billion aggregate principal amount) (the “2039 Biopharma Euronotes”)	1,387.8		1,383.6
3.25% senior unsecured notes due 2029 (the “2039 Biopharma Notes”)	889.0		890.3
4.375% senior unsecured notes due 2045 (the “2045 U.S. Notes”)	499.4		499.4
1.8% senior unsecured notes due 2049 (€750.0 million aggregate principal amount) (the “2049 Biopharma Euronotes”)	833.3		830.9
3.4% senior unsecured notes due 2049 (the “2049 Biopharma Notes”)	888.5		890.2
Other	34.9		76.3
Total debt	22,387.2		21,729.1
Less: currently payable	17.2		212.4
Long-term debt	$	22,370.0	$	21,516.7

Key Terms of Euronotes Offering

The following summarizes the key terms of the offerings in aggregate (€ in millions):

	Issue Date	Aggregate Principal Amount		Stated Annual Interest Rate		Issue Price (as % of Principal Amount)		Maturity Date	Interest Payment Dates (in arrears)
2024 Euronotes	March 30, 2020	€	750.0	1.700	%	99.931	%	March 30, 2024	March 30
2024 Euronotes	April 8, 2020	€	150.0	1.700	%	100.298	%	March 30, 2024	March 30
2026 Euronotes	March 30, 2020	€	500.0	2.100	%	99.717	%	September 30, 2026	September 30
2026 Euronotes	April 8, 2020	€	300.0	2.100	%	100.842	%	September 30, 2026	September 30
2030 Euronotes	March 30, 2020	€	500.0	2.500	%	99.642	%	March 30, 2030	March 30
2030 Euronotes	April 8, 2020	€	300.0	2.500	%	102.166	%	March 30, 2030	March 30

The components of the Company’s debt were as follows ($ in millions):

	July 3, 2020		December 31, 2019
Euro-denominated commercial paper (€1.5 billion and €4.6 billion, respectively)	$	1,680.4	$	5,146.2
U.S. dollar-denominated commercial paper	67.1		—
Zero-coupon LYONs due 2021	26.2		33.6
0.352% senior unsecured notes due 2021 (¥30.0 billion aggregate principal amount) (the “2021 Yen Notes”)	278.9		275.8
1.7% senior unsecured notes due 2022 (€800.0 million aggregate principal amount) (the “2022 Euronotes”)	897.7		894.8
Floating rate senior unsecured notes due 2022 (€250.0 million aggregate principal amount) (the “Floating Rate 2022 Euronotes”)	280.7		279.8
2.05% senior notes due 2022 (the “2022 Biopharma Notes”)	697.5		696.9
0.5% senior unsecured bonds due 2023 (CHF 540.0 million aggregate principal amount) (the “2023 CHF Bonds”)	572.2		558.9
1.7% senior notes due 2024 (€900.0 million aggregate principal amount) (the “2024 Euronotes”)	1,006.6		—
5-year revolving credit facility	1,247.8		—
2.2% senior unsecured notes due 2024 (the “2024 Biopharma Notes”)	696.4		696.2
2.5% senior unsecured notes due 2025 (€800.0 million aggregate principal amount) (the “2025 Euronotes”)	896.3		893.7
3.35% senior unsecured notes due 2025 (the “2025 U.S. Notes”)	497.5		497.3
0.2% senior unsecured notes due 2026 (€1.3 billion aggregate principal amount) (the “2026 Biopharma Euronotes”)	1,396.5		1,392.3
2.1% senior notes due 2026 (€800.0 million aggregate principal amount) (the “2026 Euronotes”)	895.1		—
0.3% senior unsecured notes due 2027 (¥30.8 billion aggregate principal amount) (the “2027 Yen Notes”)	285.6		282.5
1.2% senior unsecured notes due 2027 (€600.0 million aggregate principal amount) (the “2027 Euronotes”)	670.1		668.0
0.45% senior unsecured notes due 2028 (€1.3 billion aggregate principal amount) (the “2028 Biopharma Euronotes”)	1,394.6		1,390.1
1.125% senior unsecured bonds due 2028 (CHF 210.0 million aggregate principal amount) (the “2028 CHF Bonds”)	226.1		221.0
2.6% senior unsecured notes due 2029 (the “2029 Biopharma Notes”)	794.5		794.8
2.5% senior notes due 2030 (€800.0 million aggregate principal amount) (the “2030 Euronotes”)	898.7		—
0.75% senior unsecured notes due 2031 (€1.8 billion aggregate principal amount) (the “2031 Biopharma Euronotes”)	1,954.6		1,948.7
0.65% senior unsecured notes due 2032 (¥53.2 billion aggregate principal amount) (the “2032 Yen Notes”)	493.2		487.8
1.35% senior unsecured notes due 2039 (€1.3 billion aggregate principal amount) (the “2039 Biopharma Euronotes”)	1,387.8		1,383.6
3.25% senior unsecured notes due 2029 (the “2039 Biopharma Notes”)	889.0		890.3
4.375% senior unsecured notes due 2045 (the “2045 U.S. Notes”)	499.4		499.4
1.8% senior unsecured notes due 2049 (€750.0 million aggregate principal amount) (the “2049 Biopharma Euronotes”)	833.3		830.9
3.4% senior unsecured notes due 2049 (the “2049 Biopharma Notes”)	888.5		890.2
Other	34.9		76.3
Total debt	22,387.2		21,729.1
Less: currently payable	17.2		212.4
Long-term debt	$	22,370.0	$	21,516.7